# Iradimed Corp: overview IRMD · Nasdaq · CIK 1325618 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/irmd.md) · [Financials](/companies/irmd/financials.md) · [Filings](/companies/irmd/filings.md) · [Insiders](/companies/irmd/insiders.md) Latest reported revenue: [$20.5m](/filings/0001628280-26-051402.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Jul 31, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001628280-26-051402). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [18.3](/filings/0001104659-25-105538.md) | [19.4 d](/filings/0001104659-26-024691.md) | [19.5](/filings/0001628280-26-029325.md) | [20.4](/filings/0001628280-26-051402.md) | [21.2](/filings/0001104659-25-105538.md) | [22.7 d](/filings/0001104659-26-024691.md) | [22.0](/filings/0001628280-26-029325.md) | [20.5](/filings/0001628280-26-051402.md) | | Gross margin | % | [77.4%](/filings/0001104659-25-105538.md) | [76.1% d](/filings/0001104659-26-024691.md) | [76.1%](/filings/0001628280-26-029325.md) | [78.2%](/filings/0001628280-26-051402.md) | [77.8%](/filings/0001104659-25-105538.md) | [75.1% d](/filings/0001104659-26-024691.md) | [76.5%](/filings/0001628280-26-029325.md) | [74.1%](/filings/0001628280-26-051402.md) | | Operating margin | % | [31.6%](/filings/0001104659-25-105538.md) | [29.9% d](/filings/0001104659-26-024691.md) | [27.8%](/filings/0001628280-26-029325.md) | [33.3%](/filings/0001628280-26-051402.md) | [32.2%](/filings/0001104659-25-105538.md) | [31.3% d](/filings/0001104659-26-024691.md) | [32.9%](/filings/0001628280-26-029325.md) | [31.2%](/filings/0001628280-26-051402.md) | | Net margin | % | [27.6%](/filings/0001104659-25-105538.md) | [26.5% d](/filings/0001104659-26-024691.md) | [24.0%](/filings/0001628280-26-051402.md) | [28.3%](/filings/0001628280-26-051402.md) | [26.3%](/filings/0001104659-25-105538.md) | [28.4% d](/filings/0001104659-26-024691.md) | [26.5%](/filings/0001628280-26-051402.md) | [25.5%](/filings/0001628280-26-051402.md) | | Diluted EPS | $ per share | [0.40](/filings/0001104659-25-105538.md) | not reported | [0.37](/filings/0001628280-26-029325.md) | [0.45](/filings/0001628280-26-051402.md) | [0.43](/filings/0001104659-25-105538.md) | not reported | [0.45](/filings/0001628280-26-029325.md) | [0.41](/filings/0001628280-26-051402.md) | | Free cash flow | $m | [5.3 d](/filings/0001104659-25-105538.md) | [3.2 d](/filings/0001104659-26-024691.md) | [0.6](/filings/0001628280-26-029325.md) | [5.1 d](/filings/0001628280-26-051402.md) | [5.8 d](/filings/0001104659-25-105538.md) | [5.6 d](/filings/0001104659-26-024691.md) | [7.9](/filings/0001628280-26-029325.md) | [5.8 d](/filings/0001628280-26-051402.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [41.8](/filings/0001104659-23-028003.md) | [53.3](/filings/0001558370-24-002235.md) | [65.6](/filings/0001558370-25-011853.md) | [73.2](/filings/0001104659-26-024691.md) | [83.8](/filings/0001104659-26-024691.md) | | Gross margin | % | [76.6%](/filings/0001104659-23-028003.md) | [77.4%](/filings/0001558370-24-002235.md) | [76.5%](/filings/0001558370-25-011853.md) | [76.9%](/filings/0001104659-26-024691.md) | [76.7%](/filings/0001104659-26-024691.md) | | Operating margin | % | [23.5%](/filings/0001104659-23-028003.md) | [29.3%](/filings/0001558370-24-002235.md) | [30.6%](/filings/0001558370-25-011853.md) | [30.0%](/filings/0001104659-26-024691.md) | [31.2%](/filings/0001104659-26-024691.md) | | Net margin | % | [22.3%](/filings/0001104659-23-028003.md) | [24.1%](/filings/0001558370-24-002235.md) | [26.2%](/filings/0001558370-25-011853.md) | [26.3%](/filings/0001104659-26-024691.md) | [26.8%](/filings/0001104659-26-024691.md) | | Diluted EPS | $ per share | [0.74](/filings/0001104659-23-028003.md) | [1.02](/filings/0001558370-24-002235.md) | [1.35](/filings/0001558370-25-011853.md) | [1.50](/filings/0001104659-26-024691.md) | [1.75](/filings/0001104659-26-024691.md) | | Free cash flow | $m | [10.8](/filings/0001104659-23-028003.md) | [9.2](/filings/0001558370-24-002235.md) | [6.0](/filings/0001558370-25-011853.md) | [17.6](/filings/0001104659-26-024691.md) | [17.2](/filings/0001104659-26-024691.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/irmd/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $92.5m | 967,825 | | Added +38 | | [KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC](/funds/1021223.md) | 2026-06-30 | $37.9m | 396,982 | | Added +47,666 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $37.7m | 394,412 | | Reduced −46,300 | | [Copeland Capital Management, LLC](/funds/1541743.md) | 2026-06-30 | $37.4m | 391,860 | | Added +32,535 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $34.9m | 364,937 | | Added +6,317 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $27.7m | 290,109 | | Added +3,546 | | [Nine Ten Capital Management LLC](/funds/1635236.md) | 2026-06-30 | $24.5m | 256,562 | | Reduced −77,926 | | [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $21.9m | 229,340 | | Added +3,194 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $21.2m | 221,512 | | Added +16,984 | | [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $20.5m | 214,151 | | Added +16,206 | ## Recent filings [All 771 filings](/companies/irmd/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-30 | 16:16 ET | [10-Q](/filings/0001628280-26-068576.md) | Quarterly report, period 2026-09-30 | 0001628280-26-068576 | | 2026-10-30 | 08:37 ET | [8-K](/filings/0001628280-26-068454.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-068454 | | 2026-08-18 | 14:03 ET | [8-K/A](/filings/0001628280-26-057617.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-057617 | | 2026-07-31 | 16:09 ET | [10-Q](/filings/0001628280-26-051402.md) | Quarterly report, period 2026-06-30 | 0001628280-26-051402 | | 2026-07-31 | 08:15 ET | [8-K](/filings/0001628280-26-051240.md) | 8.01 Other events | 0001628280-26-051240 | | 2026-06-24 | 10:22 ET | [8-K](/filings/0001628280-26-045059.md) | 5.07 Shareholder vote results | 0001628280-26-045059 | | 2026-05-01 | 16:08 ET | [10-Q](/filings/0001628280-26-029325.md) | Quarterly report, period 2026-03-31 | 0001628280-26-029325 | | 2026-05-01 | 08:45 ET | [8-K](/filings/0001628280-26-029125.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-029125 | | 2026-04-30 | 16:14 ET | [DEF 14A](/filings/0001628280-26-028903.md) | Proxy statement, period 2026-06-23 | 0001628280-26-028903 | | 2026-03-06 | 16:05 ET | [10-K](/filings/0001104659-26-024691.md) | Annual report, period 2025-12-31 | 0001104659-26-024691 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-024691.md), filed Mar 6, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/bcd0c2d0-cc90-4810-9b59-82c79b97821f) ## About the filer - CIK: 1325618 - Tickers: IRMD - Exchange: Nasdaq - SIC code: 3841 Surgical & Medical Instruments & Apparatus - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 16:24 ET. No prices; not investment advice.